{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-011401","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.654318+00:00","generated_at":"2026-06-23T23:54:52.476546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zomedica Q2 2022 revenue $4.2M, up 51% pro-forma; net loss $5.3M, cash $186.8M","bullets":["Revenue $4.2M (71% gross margin), up 51% pro-forma vs combined $2.8M in Q2 2021.","PulseVet revenue $4.2M (+48% standalone); small animal systems sold 22 (20x increase).","Net loss $5.3M ($0.005/sh) vs $4.7M loss in Q2 2021; 6-month loss $9.2M ($0.009/sh).","Cash $186.8M; used $5.5M in quarter including $1M convertible note in SMP (VetGuardian).","Post-quarter acquisitions: Revo 2 imaging assets and Assisi LOOP/Calmer Canine products."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-011401","json":"https://secwatch.observer/filing/0001654954-22-011401.json","markdown":"https://secwatch.observer/filing/0001654954-22-011401.md","text":"https://secwatch.observer/filing/0001654954-22-011401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422011401/0001654954-22-011401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422011401/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:54:52.476546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}